证券代码：688105 证券简称：诺唯赞 公告编号：2024-065 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/2/6，由公司董事长兼总经理、实际控制人 | | | --- | --- | --- | | | 曹林先生提议 | | | 回购方案实施期限 | 公司董事会审议通过后 12 个月 | | | 预计回购金额 | 8,000 万元 | 万元~16,000 | | 回购用途 | | √减少注册资本 | | | □用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 4,317,099 | 股 | | 累计已回购股数占总股本比例 | 1.07% | | | 累计已回购金额 | 10,438.22 | 万元 | | 实际回购价格区间 | 17.65 元/股 | 元/股~28.65 | 一、 回购股份的基本 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2024-064 南京诺唯赞生物科技股份有限公司 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 2,123,843 股。 本次股票上市流通总数为 2,123,843 股。 南京诺唯赞生物科技股份有限公司（以下简称"公司"）于近日收到中国证 券登记结算有限责任公司上海分公司出具的《过户登记确认书》及《证券变更登 记证明》，已根据中国证券监督管理委员会、上海证券交易所、中国证券登记结 算有限责任公司上海分公司相关业务规定，完成了公司 2023 年限制性股票激励计 划（以下简称"本激励计划"）首次授予部分第一个归属期的股份登记工作。现 将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2023 年 8 月 28 日，公司召开第二届董事会第四次会议，审议通过了《关 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请股东大会授权 1 关于 2023 年限制性股票激励计划首次授予部分 第一个归属期归属结果暨股份上市公 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2024-063 南京诺唯赞生物科技股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 11 月 20 日(星期三) 至 11 月 27 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 irm@vazyme.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 11 月 29 日（星期五）上午 11:00-12:00 （二） 会议召开地点：上证路演中心（roadshow.sseinfo.com） 1 会议召开时间：2024 年 11 月 29 日(星期五)上午 11:00-12:00 会议召开地点：上证路演中心（roadshow.sseinfo.com） 会议召开方式：上证路演中心网络互动 证券代码：688105 证券简称：诺唯赞 公告编号：2024-06 ...

Investment Rating - The report maintains a "Buy" rating for the company [1][3] Core Views - New product launches and overseas market expansion drive steady revenue growth, while cost reduction and efficiency improvements boost gross margins [1] - Strong downstream demand for GLP-1 drives high growth in the biopharmaceutical sector, with the life sciences business showing good growth momentum and international business becoming a second growth curve [1] - The company strategically focuses on downstream blockbuster products, with progress in respiratory pathogens, AD blood testing, and microfluidic products, opening long-term growth potential [1] Financial Performance - Q1-Q3 2024 revenue reached RMB 986 million, up 13.42% YoY, with net profit attributable to shareholders of RMB 18.16 million, up 123.77% YoY [1] - Q3 2024 revenue was RMB 337 million, up 12.87% YoY, but net profit attributable to shareholders declined 57.55% YoY to RMB 2 million [1] - Q3 2024 gross margin improved to 69.97%, up 1.64 percentage points YoY, reflecting cost reduction and efficiency gains [1] Business Segment Performance - Life Sciences: Q3 2024 revenue was approximately RMB 260 million, up 14% YoY, with cell protein business growing over 120% and international business revenue reaching RMB 23 million [1] - Biopharmaceuticals: Q3 2024 revenue was approximately RMB 50 million, up 40% YoY, driven by GLP-1 business [1] - In Vitro Diagnostics: Revenue declined sequentially due to off-season for respiratory pathogen testing and ongoing market promotion for AD testing products [1] Strategic Focus - Respiratory Pathogens: Products for influenza A/B and Mycoplasma pneumoniae have obtained registration certificates, with over 500 hospitals onboarded [1] - AD Blood Testing: Six AD blood testing indicators were approved in April 2024, with equipment expected to complete registration by year-end and 200-300 hospitals targeted for installation [1] - Microfluidics: Completed development and EU registration for a 6-plex upper respiratory infection test, with plans for additional products targeting Europe, the Middle East, and Southeast Asia [1] Financial Projections - Revenue for 2024-2026 is projected to be RMB 1.44 billion, RMB 1.79 billion, and RMB 2.25 billion, with YoY growth of 12.0%, 24.6%, and 25.2% respectively [1] - Net profit attributable to shareholders for 2024-2026 is projected to be RMB 31 million, RMB 152 million, and RMB 273 million, with YoY growth of 144.1%, 385.4%, and 79.6% respectively [1] - PE ratios for 2024-2026 are projected at 308X, 63X, and 35X [1]

编号：2024-11-1 证券简称：诺唯赞 证券代码：688105 南京诺唯赞生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |---------------------------------------------------------|------------------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Summary of Conference Call Company and Industry Overview - The conference call discusses the financial performance and business developments of a company in the life sciences and biopharmaceutical industry, focusing on its revenue growth and strategic initiatives in various business segments [1][2][3]. Key Financial Metrics - In Q3 2023, the company achieved a revenue of 337 million yuan, representing a year-over-year growth of approximately 13% [1]. - For the first three quarters of 2023, total revenue reached 986 million yuan, with a year-over-year increase of nearly 14% [1]. - The company reported a quarterly operating profit of over 2 million yuan, with a year-to-date operating profit of approximately 18 million yuan [5]. Business Segments Performance Life Sciences Segment - The life sciences segment generated 260 million yuan in Q3, with a year-over-year growth of 14% [2]. - The growth in this segment is attributed to the introduction of new products, particularly in cell protein, which saw over 120% growth [2][3]. - The company is experiencing a slowdown in traditional business growth due to market demand and competition [2]. Biopharmaceutical Segment - The biopharmaceutical segment reported nearly 50 million yuan in revenue for Q3, with a year-over-year growth of 40% and a quarter-over-quarter growth of 30% [3]. - The growth is driven by the increase in sales of specific products and favorable market conditions [3][4]. IoT Segment - The IoT segment showed weaker performance in Q3, attributed to seasonal factors and inventory adjustments, resulting in a decline compared to Q2 [4]. Strategic Initiatives - The company is transitioning to focus on high-value products with larger customer bases and less competition, aiming to enhance its market position [6][7]. - There is a strong emphasis on research and development, with significant investments in key projects related to respiratory diseases, Alzheimer's disease (AD), and microfluidics [21][22]. - The company plans to expand its market presence through partnerships and collaborations, particularly in overseas markets [24][27]. Market Trends and Future Outlook - The company anticipates a growing demand for blood testing and related products, with a focus on early detection and intervention for diseases like Alzheimer's [8][9]. - The market for biopharmaceuticals, particularly in the treatment of Alzheimer's, is expected to expand significantly, with the company positioning itself to capitalize on this trend [12][15]. - The company is exploring opportunities for mergers and acquisitions to enhance its product offerings and market reach [30][31]. Additional Insights - The company is actively developing a new product for Alzheimer's detection, which has shown promising early results in clinical trials [36][37]. - There is a notable trend towards the integration of advanced technologies in diagnostics, which the company aims to leverage for competitive advantage [19][20]. This summary encapsulates the key points discussed during the conference call, highlighting the company's financial performance, business segment developments, strategic initiatives, and future market outlook.

证券代码：688105 证券简称：诺唯赞 公告编号：2024-062 南京诺唯赞生物科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 1 证券代码：688105 证券简称：诺唯赞 公告编号：2024-052 公司股份的回购报告书》（公告编号：2024-003、004）。 公司分别于2024年5月6日、2024年6月6日召开第二届董事会第十次会议和 2023年年度股东大会，审议通过了《关于变更回购股份方案的议案》。为维护广大 投资者利益，增强投资者信心，公司结合实际情况，对本次回购股份方案的回购 股份用途进行调整，由"用于实施股权激励或员工持股计划"调整为"用于注销 并相应减少注册资本"，涉及的具体股份数量以本次回购完成后的回购股份总数为 准。具体内容详见公司分别于2024年5月7日、2024年6月7日在上海证券交易所网 站（www.sse.com.cn）披露的《关于变更回购股份用途的公告》《2023年年度股东 大会决议公告》（公告编号：2024-030、038）。 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [9]. Core Views - The company achieved a revenue of 986 million yuan in the first three quarters of 2024, representing a year-on-year growth of 13.42%. The net profit attributable to shareholders was 18 million yuan, with a significant year-on-year increase of 123.77% [1]. - The company is experiencing robust growth in its life sciences and biopharmaceutical sectors, with a steady performance in its IVD (in vitro diagnostics) business. The introduction of high-performance products and breakthroughs in overseas markets are expected to drive rapid growth in related reagent products [1][2]. - The company has actively expanded its overseas business since 2022, leveraging differentiated solutions that combine reagents, consumables, and equipment. This strategy has led to significant breakthroughs in North America, Europe, and Southeast Asia, enhancing delivery efficiency and contributing to revenue growth [1][2]. Summary by Sections Financial Performance - For Q3 2024, the company reported a revenue of 337 million yuan, a year-on-year increase of 12.87%. The net profit attributable to shareholders was 2 million yuan, a decline of 57.55% year-on-year, while the non-recurring net profit was -15 million yuan, showing a year-on-year growth of 30.88% [1][3]. - The gross profit margin for the first three quarters of 2024 was 70.48%, a slight decrease of 0.45 percentage points year-on-year. The net profit margin improved by 10.67 percentage points year-on-year to 1.73% [1][2]. Cost Management - The sales expense ratio for the first three quarters of 2024 was 34.21%, down by 3.70 percentage points year-on-year. The management expense ratio was 16.47%, a decrease of 3.43 percentage points, and the R&D expense ratio was 21.76%, down by 6.85 percentage points [1][2]. Growth Forecast - The revenue forecast for 2024-2026 is adjusted to 1.416 billion yuan, 1.779 billion yuan, and 2.191 billion yuan, respectively, with year-on-year growth rates of 10%, 26%, and 23%. The net profit attributable to shareholders is projected to be 33 million yuan, 196 million yuan, and 314 million yuan for the same period, with year-on-year growth rates of 147%, 493%, and 60% [1][2].

表决结果：同意 3 票，反对 0 票，弃权 0 票。 监事会认为，公司 2024 年第三季度报告的编制和审议程序符合相关法律法 规及《公司章程》等内部规章制度的规定，内容与格式符合相关规定，真实、准 确、完整地反映了公司 2024 年第三季度的财务状况和经营成果等事项，不存在 任何虚假记载、误导性陈述或重大遗漏。在 2024 年第三季度报告编制过程中， 未发现公司参与报告编制和审议的人员有违反保密规定的行为。 证券代码：688105 证券简称：诺唯赞 公告编号：2024-057 报告具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn） 的《2024 年第三季度报告》。 南京诺唯赞生物科技股份有限公司 第二届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 南京诺唯赞生物科技股份有限公司(以下简称"公司")第二届监事会第十一 次会议（以下简称"会议"）于 2024 年 10 月 25 日以邮件方式向全体监事发出会 议通知，并于 2024 年 10 月 30 日以现场表决的方式 ...

证券代码：688105 证券简称：诺唯赞 公告编号：2024-059 南京诺唯赞生物科技股份有限公司 关于拟对外投资设立控股公司暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 南京诺唯赞生物科技股份有限公司（以下简称"公司"）下属全资子公 司海南诺唯赞生物科技有限公司（以下简称"海南诺唯赞"）拟与海南嘉耀投资 合伙企业（有限合伙）（以下简称"海南嘉耀"）、海南晟健投资合伙企业（有 限合伙）（以下简称"海南晟健"）共同于英国投资设立控股公司 Logilet（UK） Limited（暂定名，以最终注册信息为准，以下简称"Logilet（UK）"或"新设 公司"），拟主要从事 Logicore 数字微流控系统在海外区域的市场准入、商业 推广和销售业务。新设公司注册资本为 1,000 万元人民币，约折合 137.93 万美 元，其中：海南诺唯赞拟直接投资，出资总额为 650 万元人民币，约折合 89.66 万美元，占比 65%；海南嘉耀拟通过全资子公司英属维尔京群岛公司 Newrgy Capita ...